Sermorelin Acetate

Sermorelin Acetate

Sermorelin Acetate is a synthetic peptide corresponding to the biologically active N-terminal 29-amino acid fragment of endogenous growth hormone-releasing hormone (GHRH 1-29 NH2). It is the shortest GHRH fragment known to retain full biological activity at the GHRH receptor, making it a well-characterised and widely used research tool for studying the somatotropic axis. Sermorelin has been extensively investigated in preclinical and clinical research contexts for its capacity to stimulate pulsatile growth hormone secretion from the anterior pituitary.

Mechanism of Action

Sermorelin binds to and activates the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH) via a cAMP-dependent signalling cascade. The resulting GH elevation promotes hepatic IGF-1 production, which mediates downstream anabolic, lipolytic, and tissue-remodelling effects. Unlike exogenous GH administration, sermorelin preserves the physiological feedback regulation of the hypothalamic-pituitary-somatotropic axis, including somatostatin-mediated inhibition, making it a valuable tool for studying GHRH receptor pharmacology and GH secretion dynamics.

Research Applications

• GHRH receptor pharmacology and pituitary somatotroph function studies
• Growth hormone secretion, pulsatility, and feedback regulation research
• IGF-1 axis dynamics and downstream anabolic signalling investigation
• Age-related GH decline and somatopause modelling
• Body composition, lipolysis, and metabolic regulation research

Specifications

• Molecular Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
• Molecular Weight: 3357.9 g/mol
• CAS Number: 86168-78-7
• Purity: ≥98%
• Form: Lyophilised powder
• Storage: -20°C
• Shelf Life: 24 months

This product is intended for legitimate laboratory and analytical research use only. Not for diagnostic, therapeutic, or consumer use.